BIOMAT Database Logo BIOMAT Database Logo

Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. 1993

I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Developmental Vascular Biology and Pharmacology Unit, United Medical School, Guy's Hospital, London, UK.

BACKGROUND The pathogenesis of pulmonary vascular disease in children with congenital heart disease is incompletely understood. Thromboxane (TX) A2 and prostacyclin (PGI2) have opposing effects on platelet aggregation and pulmonary vascular smooth muscle. An imbalance in their biosynthesis could contribute to the progressive increase in pulmonary vascular resistance seen in older untreated patients with pulmonary hypertensive congenital heart disease and the thrombotic complications they may develop. RESULTS We investigated TXA2 and PGI2 biosynthesis in 15 young children (0.2 to 2.25 years old) with congenital heart disease with increased pulmonary blood flow and potentially reversible pulmonary vascular disease by measuring urinary excretion of 2,3-dinor-TXB2 and 2,3-dinor-6-oxoprostaglandin (PG) F1 alpha and compared the findings with those in 16 healthy children (0.5 to 2.8 years old). 2,3-Dinor-TXB2 excretion was greater in the patients than in control subjects (1253 +/- 161 versus 592 +/- 122 ng/g creatinine; P < .001). Excretion of 2,3-dinor-6-oxo-PGF1 alpha was 452 +/- 54 compared with 589 +/- 95 ng/g creatinine in control subjects. In 5 patients who underwent successful cardiac surgery > or = 1 year later excretion of 2,3-dinor-TXB2 decreased from 1100 +/- 298 to 609 +/- 131 ng/g creatinine (P < .05), a value comparable to those in 5 healthy children of similar age (749 +/- 226 ng/g creatinine). We also compared 15 patients (11 to 23 years old) with advanced irreversible pulmonary vascular disease with 19 healthy control subjects (10 to 23 years old). The ratio of TX to PGI2 metabolite excretion was greater in the patients than in control subjects (3.5 +/- 0.6 versus 2.0 +/- 0.3; P < .05). CONCLUSIONS There is increased 2,3-dinor-TXB2 excretion in children with congenital heart disease and a high pulmonary blood flow that may reflect an imbalance in biosynthesis of TXA2 and PGI2 in the pulmonary vascular bed. The imbalance may contribute to the progressive development of increased pulmonary vascular resistance and persists in older patients whose heart defects are uncorrected.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D011660 Pulmonary Heart Disease Hypertrophy and dilation of the RIGHT VENTRICLE of the heart that is caused by PULMONARY HYPERTENSION. This condition is often associated with pulmonary parenchymal or vascular diseases, such as CHRONIC OBSTRUCTIVE PULMONARY DISEASE and PULMONARY EMBOLISM. Cor Pulmonale,Disease, Pulmonary Heart,Diseases, Pulmonary Heart,Heart Disease, Pulmonary,Heart Diseases, Pulmonary,Pulmonary Heart Diseases
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females

Related Publications

I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Increased prostacyclin and thromboxane A2 biosynthesis in atherosclerosis.
June 1988, Proceedings of the National Academy of Sciences of the United States of America,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Biosynthesis of prostacyclin and thromboxane A2 during chronic hypoxaemia in children with cyanotic congenital heart disease.
December 1996, European journal of clinical investigation,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A2 and prostacyclin.
August 2010, American journal of medical genetics. Part A,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
On the mechanism of prostacyclin and thromboxane A2 biosynthesis.
January 1989, The Journal of biological chemistry,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Prostacyclin and thromboxane A2 synthesis by rabbit pulmonary artery.
October 1980, The Journal of pharmacology and experimental therapeutics,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Pulmonary vascular responses to thromboxane and prostacyclin.
December 1992, Journal of applied physiology (Bethesda, Md. : 1985),
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
[Stenocardia. Thromboxane A2 and prostacyclin].
July 1986, Kardiologiia,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Prostacyclin, thromboxane A2, and hypertension.
December 1990, Clinical and investigative medicine. Medecine clinique et experimentale,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Thromboxane A2 biosynthesis in human disease.
January 1987, Federation proceedings,
I Adatia, and S E Barrow, and P D Stratton, and V M Miall-Allen, and J M Ritter, and S G Haworth
Prostacyclin and thromboxane A2 levels in children and adolescents with an inherited predisposition to coronary heart disease: a family study.
September 1994, Coronary artery disease,
Copied contents to your clipboard!